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Germ cell tumours (GCT) comprise exquisitely chemosensitive
neoplasms, and cure is possible in patients presenting with a high
metastatic tumour burden. For the few patients with high-risk
disease or who relapse after first-line chemotherapy, the admin-
istration of a tandem or a triple course of high-dose chemotherapy
(HDCT) with carboplatin and etoposide with stem cell support may
represent a valuable therapeutic option.1–3 Although GCT remains
the most frequent solid tumour in young adults, evidence of a
shift towards older age at diagnosis has been reported by many
authors.4 Furthermore, increasing age at diagnosis has been
reported to have a poor prognostic effect in GCT patients
receiving first-line chemotherapy.5–7 In a large study by Danish
authors and another double-institution dataset, age was identified
as a statistically significant poor prognostic factor in multivariable
analyses. For this reason, it is possible that older patients with GCT
have an inherently negative prognostic factor related to their age,
which may partly explain the inability to administer timely curative
chemotherapy in some cases due to the haematological toxicity of
bleomycin, etoposide, and cisplatin (BEP) chemotherapy.8–12
In general, for patients aged 40 years or older, there are
concerns regarding the possibility of administering standard
chemotherapy in a timely manner and preserving the full dose
of all drugs throughout the treatment course. In the case of HDCT
administration, limited data are available for older GCT patients,
and the benchmark safety data can be transferred from
haematologic neoplasms. Obtaining robust information that HDCT
can be safely administered in this patient population may help
clinicians in the decision-making process and patient counselling,
given the uncertainties regarding the optimal salvage therapeutic
strategy.
For this reason, we conducted a retrospective study on the
database of the European Society for Blood and Marrow
Transplantation (EBMT)—Solid Tumors Working Party (STWP).
The study aimed to analyse the incidence of severe side effects
following HDCT administration in patients aged more than
40 years at the time of first HDCT course. Statistical analyses
relied on transplant-related mortality (TRM) as the primary
endpoint. Summary statistics were used to describe patient
characteristics and outcomes, and the reverse Kaplan–Meier
method described by Schemper and Smith was used for follow-up
quantification.13 TRM was defined as mortality from any cause
other than disease progression within 100 days of HDCT. Logistic
multivariable models were constructed with the following
variables: treatment period (1981–1989; 1990–1999; 2000–2015),
age, conditioning regimen type and stem-cell source. Multiple
imputation was used to account for the missing data, and
supportive analyses were performed through the complete-case
data set. Statistical analyses were performed with SAS (version 9.2,
SAS Institute, Cary, NC, USA) and R software (version 3.2.3,
R Foundation for Statistical Computing, Vienna, Austria). Statistical
significance was set at the conventional 5% two-sided threshold.
From November 1981 to December 2015, 1179 patients aged
⩾40 years were identified from a total of 5295 registered patients
(22%) from 226 EBMT centres. The median follow-up was
36.6 months (interquartile range: 9.3–99.5 months). The flow of
patient selection is described in Supplementary Figure 1. A total of
1169 patients with the suitable data were included in the final
analyses. The distribution of the main baseline characteristics is
provided in Supplementary Table 1, together with their TRM rate.
There were 909 patients aged 40–49, 234 aged 50–59 and 26 cases
aged
60 years or older. HDCT consisted of the administration of
carboplatin and etoposide in 382 patients, whereas 349 patients
received mixed HDCT regimens (the information was not available
in 438 cases). Table 1 provides subgroup analyses on the TRM rate
according to the combination of the main factors. In this case,
treatment period was split in 1981–1999 and 2000–2015 due to the
small numbers. The highest TRM rate was noted in the earliest
period, as expected (12.5%), but very few HD-carboplatin-etoposide
courses were administered in this period. Most of the cases received
HD-carboplatin and etoposide in the years 2000–2015, in which the
TRM rate was 3.2%. In addition, TRM with this regimen ranged from
2.5 to 3.5% across the age subgroups (data not shown).
Results of the logistic multivariable model are provided in
Table 2 after multiple imputation of missing data. Notably, only
the type of conditioning regimen (i.e., carboplatin-etoposide
HDCT regimen vs other) was significantly associated with TRM
Table 1. Subgroup analysis for transplant-related mortality of patients








N % N %
1981–1999 CBDCA-VP16 6/6 100.0 — —
Mixed 84/96 87.5 12/96 12.5
NA 144/155 92.9 11/155 7.1
2000–2015 CBDCA-VP16 364/376 96.8 12/376 3.2
Mixed 234/253 92.5 19/253 7.5
NA 263/283 92.9 20/283 7.1
Total 1095/1169 93.7 74/1169 6.3
Abbreviations: CBDCA= carboplatin; GCT= germ cell tumours; NA=not
available; TRM= transplant-related mortality; VP16= etoposide.
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(odds ratio: 0.40, 95%CI: 0.18–0.89, P= 0.024). The same results
were obtained in the complete-case multivariable analyses
(Supplementary Table 2).
The main causes of TRM are presented in Supplementary Table 3.
As noted, the majority of patients (28.4%) died from infections and
the development of septic shock in addition to other cases who
died as a consequence of organ failure or haemorrhage.
To our knowledge, we present one of the largest studies on the
incidence of TRM in patients receiving HDCT after the age of 40
regardless of the tumour type. Additionally, we provide the first
study of this type focusing on GCT patients. The evidence clearly
corroborates the feasibility of the preferred modern approach that
favours the administration of multiple courses of HD-carboplatin
and etoposide in the very rare population of older patients.
Interestingly, in the largest European registry of HDCT, 23.1% of
patients with GCT received treatment with at the age of 40 years
or older, representing a significant number of patients among
those who received autologous transplantation for GCT. This
information was mostly unknown to us prior to the present
analysis. Of course, some biases should be accounted for when
interpreting the findings, which are mainly attributable to the
limits of retrospective, long-dated analyses. First, and most
importantly, we could not finely analyse the tolerability of HDCT
administration, for example, by including the additional data on
the incidence of severe acute and long-term side effects, given the
lack of suitable data. Second, we did not have information
regarding the number of chemotherapy regimens administered in
each case prior to HDCT. This information may be important as the
burden of prior chemotherapies is likely to negatively affect the
TRM risk; however, the rate of TRM after carboplatin and etoposide
was generally less than 4%. The incidence of 2.5–3.5% TRM is
consistent with the reported results from a large series of HDCT in
younger GCT patients using the same conditioning regimen.
Therefore, the administration HD-carboplatin and etoposide does
not seem to be associated with an excess risk of TRM in older
patients, which is also evident from the multivariable analyses.
Third, findings that are applicable to the current practice are
ultimately those reported in the period 2000–2015 (n= 912), when
the majority of patients received both modern chemotherapy and
modern best supportive care. In addition, peripheral blood
haematopoietic stem cells were used in all cases.
In general, for older patients with GCT, concerns may be raised
about the possibility of administering standard chemotherapy in a
timely manner and preserving the full dose of all drugs in each
cycle. In a retrospective analysis from the United States, the data
on conventional-dose chemotherapy in these patients were
reported. In total, 236 patients aged ⩾ 50 years were treated,
and significant rates of neutropenic fever and haematological
severe toxicities were observed after BEP chemotherapy.11
Dose reductions, delays or treatment change were required in
30 patients. Conversely, in another English study, the authors did
not observe toxicity issues with the use of BEP chemotherapy in
60 patients who were older than 60 years.12
A comprehensive risk-benefit evaluation should include
co-morbidities and the patient’s risk category, and chemotherapy
regimens may be tailored in some cases. The prognosis is poorer for
older patients with nonseminoma histology. In the salvage setting,
informed consent should comprise adequate information on the
risks of severe toxicities from every treatment modality, including
HDCT. On the basis of our large retrospective analysis, patients
without any significant comorbidity contraindicating HDCT admin-
istration should be aware that the mortality risk due to transplant is
similar to that of younger patients, ranging from 2.5 to 3.5%.
In conclusion, the present data may aid physicians who are
treating advanced GCT to improve their knowledge of the
mortality-rate after HDCT administration in older patients. HDCT
can be safely administered in these high-risk patients and still
represents their first therapeutic option in the salvage setting,
pending prospective validation through clinical trials.
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